• By ICR Secretariat
  • Posted Wednesday, January 13, 2021

CRUK Scientists develop drug that targets KRAS pathways

http://www.pharmatimes.com/news/cruk_scientists_develop_drug_that_targets_kras_pathways_1360681

A new study, funded by Cancer Research UK (CRUK) and Wellcome, has discovered a new way to target the KRAS mutation, which is found in a number of hard-to-treat cancer types.